FindTrial
Sign In

An Open Randomized Controlled Clinical Study on Sirolimus-Based Immunosuppression for replapse and metastasis of Liver Transplantation in the Presence of Extended Criteria for Hepatocellular Carcinoma

An Open Randomized Controlled Clinical Study on Sirolimus-Based Immunosuppression for replapse and metastasis of Liver Transplantation in the Presence of Extended Criteria for Hepatocellular Carcinoma

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001802
Enrollment
Unknown
Registered
2011-12-16
Start date
2007-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver transplantation

Interventions

1:tacrolimus
2:sirolimus

Sponsors

The General Hospital of Chinese People's Armed Police Forces
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) More than 2 months in patients with hepatocellular carcinoma after liver transplantation; (2) Age of 20-70 years; (3) Preoperative transplantatio beyond milan criteria recipients; (4) oral glucocorticoids and FK506; (5) Signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients allergic against sirolimus and drug components accessories; (2) Life expectancy of less than 6 months; (3) patients with delirium or dementia, who cannot obtain informed consent; (4) Recipients are participating in other clinical studies; (5) Not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
tumor recurrence rate;—

Countries

China

Contacts

Public ContactChen Xinguo
niuyujian@yahoo.com.cn+86 10 57976840

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026